Checkpoint Therapeutics Q3 EPS $(0.29) Beats $(0.72) Estimate, Sales $31.00K Beat $10.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Checkpoint Therapeutics (NASDAQ:CKPT) reported Q3 earnings with a loss of $(0.29) per share, surpassing the $(0.72) estimate, marking a 59.72% beat and a 75.83% improvement from last year's $(1.20) loss. Sales reached $31.00K, exceeding the $10.00K estimate by 210% but showing a 35.42% decline from the previous year's $48.00K.
November 13, 2023 | 10:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Checkpoint Therapeutics reported better-than-expected Q3 EPS and sales, indicating a significant improvement over last year's performance despite a decrease in sales from the same period last year.
The positive earnings report, with a substantial beat on both EPS and sales estimates, is likely to instill investor confidence and could lead to a short-term uptick in CKPT's stock price. The improvement in earnings compared to the previous year's loss is significant, despite the sales decrease, which may be viewed as a minor setback when considering the overall positive results.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100